47P Phase I study to assess the safety and efficacy of P-BCMA-ALLO1: A fully allogeneic CAR-T therapy, in patients with relapsed/refractory multiple myeloma (RRMM)

Saved in:
Bibliographic Details
Published in:Immuno-oncology technology 2022-12, Vol.16, p.100152, Article 100152
Main Authors: Kocoglu, M.H., Asch, A., Ramakrishnan, A., Bachier, C., Martin, T., Rodriguez, T., McArthur, K., Martin, C., Namini, H., Ostertag, E., Spear, M., Christie, E., Belani, R., Zhang, M., Cranert, S., Coronella, J., Shedlock, D., Costello, C.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2590-0188
2590-0188
DOI:10.1016/j.iotech.2022.100152